Literature DB >> 16972171

Prolonged moderate-intensity exercise without and with L-carnitine supplementation in patients with MCAD deficiency.

H H Huidekoper1, J Schneider, T Westphal, F M Vaz, M Duran, F A Wijburg.   

Abstract

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is probably the most common inborn error of fatty acid oxidation (FAO). Routine L-carnitine supplementation in the treatment of MCADD is controversial. To establish the effects of L-carnitine supplementation during prolonged moderate-intensity exercise in MCADD, five patients and three control subjects were studied during 2 hours of moderate-intensity exercise after a 12-hour fast. Patients were studied twice, once with and once without L-carnitine supplementation (50 mg/kg per day). Blood samples were collected before, during and after exercise, and analysed for routine parameters, acylcarnitines and carnitine biosynthesis intermediates. Urine was collected before and after exercise, and analysed for acylcarnitines. All patients were able to complete the exercise test without any apparent clinical or biochemical adverse effects, even without L-carnitine supplementation. A significant rise in plasma free fatty acids and octanoylcarnitine levels during exercise was seen in all patients, indicating a substantial increase in FAO during exercise. Octanoylcarnitine levels in plasma were significantly higher in patients with L-carnitine supplementation, suggesting increased clearance of accumulating acylcarnitines. A statistically significant increase of plasma and urinary free carnitine levels, as well as of plasma gamma-butyrobetaine was seen in MCADD patients without L-carnitine supplementation. These data suggest an increase in carnitine biosynthesis. In conclusion, although L-carnitine supplementation may promote clearance of accumulating acylcarnitines during moderate-intensity exercise, no apparent beneficial effect of this supplementation on clinical and biochemical parameters was observed in MCADD patients. Our results suggest that MCADD patients are able to increase carnitine biosynthesis during exercise to compensate for carnitine losses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972171     DOI: 10.1007/s10545-006-0355-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  22 in total

1.  Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidaemias and fatty acid oxidation defects.

Authors:  P Vreken; A E van Lint; A H Bootsma; H Overmars; R J Wanders; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

Review 2.  Carnitine biosynthesis in mammals.

Authors:  Frédéric M Vaz; Ronald J A Wanders
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

Review 3.  Bacterial carnitine metabolism.

Authors:  H P Kleber
Journal:  FEMS Microbiol Lett       Date:  1997-02-01       Impact factor: 2.742

Review 4.  Lipid metabolism during endurance exercise.

Authors:  J F Horowitz; S Klein
Journal:  Am J Clin Nutr       Date:  2000-08       Impact factor: 7.045

5.  Carnitine metabolism during prolonged exercise and recovery in humans.

Authors:  J I Carlin; W G Reddan; M Sanjak; R Hodach
Journal:  J Appl Physiol (1985)       Date:  1986-10

Review 6.  Carnitine metabolism and its regulation in microorganisms and mammals.

Authors:  C J Rebouche; H Seim
Journal:  Annu Rev Nutr       Date:  1998       Impact factor: 11.848

7.  Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration.

Authors:  J A Romijn; E F Coyle; L S Sidossis; A Gastaldelli; J F Horowitz; E Endert; R R Wolfe
Journal:  Am J Physiol       Date:  1993-09

Review 8.  Treatment of carnitine deficiency.

Authors:  S C Winter
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 9.  Medium chain acyl-CoA dehydrogenase deficiency.

Authors:  E H Touma; C Charpentier
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

10.  Carnitine and acylcarnitine metabolism during exercise in humans. Dependence on skeletal muscle metabolic state.

Authors:  W R Hiatt; J G Regensteiner; E E Wolfel; L Ruff; E P Brass
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more
  4 in total

1.  Normal rates of whole-body fat oxidation and gluconeogenesis after overnight fasting and moderate-intensity exercise in patients with medium-chain acyl-CoA dehydrogenase deficiency.

Authors:  Hidde H Huidekoper; Mariëtte T Ackermans; René Koopman; Luc J C van Loon; Hans P Sauerwein; Frits A Wijburg
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

2.  Incidence of medium-chain acyl-CoA dehydrogenase deficiency in Canada using the Canadian Paediatric Surveillance Program: Role of newborn screening.

Authors:  Chitra Prasad; Kathy N Speechley; Sarah Dyack; Charles A Rupar; Pranesh Chakraborty; Jonathan B Kronick
Journal:  Paediatr Child Health       Date:  2012-04       Impact factor: 2.253

Review 3.  Current issues regarding treatment of mitochondrial fatty acid oxidation disorders.

Authors:  Ute Spiekerkoetter; Jean Bastin; Melanie Gillingham; Andrew Morris; Frits Wijburg; Bridget Wilcken
Journal:  J Inherit Metab Dis       Date:  2010-09-10       Impact factor: 4.982

Review 4.  Establishing core outcome sets for phenylketonuria (PKU) and medium-chain Acyl-CoA dehydrogenase (MCAD) deficiency in children: study protocol for systematic reviews and Delphi surveys.

Authors:  Beth K Potter; Brian Hutton; Tammy J Clifford; Nicole Pallone; Maureen Smith; Sylvia Stockler; Pranesh Chakraborty; Pauline Barbeau; Chantelle M Garritty; Michael Pugliese; Alvi Rahman; Becky Skidmore; Laure Tessier; Kylie Tingley; Doug Coyle; Cheryl R Greenberg; Lawrence Korngut; Alex MacKenzie; John J Mitchell; Stuart Nicholls; Martin Offringa; Andreas Schulze; Monica Taljaard
Journal:  Trials       Date:  2017-12-19       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.